Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)
Public ClinicalTrials.gov record NCT06101823. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of OpSCF in the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo. OpSCF or placebo will be administered every 2 weeks for 14 weeks, and the efficacy will be assessed two weeks later. After that, subjects may choose to enter an Open Label Extension phase in which all subjects will receive OpSCF every 4 weeks for 40 additional weeks.
Study identification
- NCT ID
- NCT06101823
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 21, 2023 (Actual)
- Primary completion
- Sep 3, 2024 (Actual)
- Completion
- Aug 18, 2025 (Actual)
- Last update posted
- Sep 11, 2026
2023 – 2025
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cahaba Dermatology & Skin Health Center | Birmingham | Alabama | 33607 | — |
| First OC Dermatology Research | Fountain Valley | California | 92708 | — |
| Axon Clinical Research | Inglewood | California | 90301 | — |
| University Clinical Trials | San Diego | California | 92123 | — |
| Unison Clinical Trials | Sherman Oaks | California | 91403 | — |
| Skin Care Research | Boca Raton | Florida | 33456 | — |
| Skin Research of South Florida | Miami | Florida | 33173 | — |
| RM Medical Research | Miami Lakes | Florida | 33014 | — |
| Advanced Clinical Research Institute | Tampa | Florida | 33607 | — |
| Arlington Dermatology | Rolling Meadows | Illinois | 60008 | — |
| Options Research Group | West Lafayette | Indiana | 47906 | — |
| DS Research of Kentucky | Louisville | Kentucky | 40241 | — |
| Oakland Hills Dermatology P.C | Auburn Hills | Michigan | 48326 | — |
| Saginaw Bay Dermatology | Bay City | Michigan | 48706 | — |
| Skin Cancer and Dermatology Institute | Reno | Nevada | 89509 | — |
| Forest Hills Dermatology Group | Kew Gardens | New York | 11415 | — |
| Rodgers Dermatology | Frisco | Texas | 75034 | — |
| Dermatology Of Seattle | Bellevue | Washington | 98004 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06101823, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 11, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06101823 live on ClinicalTrials.gov.